Macbee Planet (7095) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
10 Sep, 2026Executive summary
Q1 FY04/2027 revenue was 12,290 million yen, down 3.8% year-over-year, with gross profit at 2,085 million yen and operating profit at 764 million yen, up 1.3% year-over-year; profit attributable to owners was 442 million yen, down 12.5% year-over-year.
Revenue decline was mainly due to a client-specific event in online medical care, but gross and operating profit improved slightly.
A new management structure was implemented, with Shoda appointed as President and a renewed execution team.
Group reorganization shifted some subsidiaries to equity-method affiliates, with impacts on forecasts to be disclosed later.
The Japanese economy showed moderate recovery, but uncertainties remain due to global trade and geopolitical risks.
Financial highlights
Gross profit: 2,085 million yen (up 0.1% YoY), gross margin 17.0% (up 0.7pt YoY).
Operating profit: 764 million yen (up 1.3% YoY), operating margin 6.2% (up 0.3pt YoY).
Basic EPS: 35.53 yen (down 2.5% YoY).
Profit attributable to owners: 442 million yen (down 12.5% YoY).
Total assets at quarter-end were 23,465 million yen, down from 24,091 million yen at the previous fiscal year-end.
Outlook and guidance
Full-year FY04/2027 revenue forecast is 51,000 million yen, up 0.8% YoY; operating profit projected at 3,000 million yen (down 17.8%), profit attributable to owners at 1,900 million yen (down 19.3%), and basic EPS at 152.53 yen.
Management strategy and key metrics will be disclosed with Q2 results in December 2026.
Revised financial forecasts will be announced after group reorganization impacts are determined; dividend forecast remains unchanged.
Latest events from Macbee Planet
- Profit and revenue fell for the first time, with further profit decline expected in FY2027.7095
Q4 2026 - Revenue and profit fell sharply year-over-year, but full-year guidance is maintained.7095
Q3 2026 - Operating profit and margin fell as revenue growth slowed, leading to a downward forecast revision.7095
Q2 2026 - Q1 revenue up 11% year-over-year, but profit fell sharply on higher ad costs; recovery forecast.7095
Q1 2026 - Sales and profits more than doubled, with strong outlook and a 4-for-1 stock split ahead.7095
Q4 2024 - Record sales and profit growth, led by medical and LTV Marketing, with a major share buyback.7095
Q1 2025 - Sales up 30% in 1H, with strong growth in medical, finance, and LTV Marketing.7095
Q2 2025 - Net sales and profits rose sharply, with upgraded guidance and strong LTV Marketing growth.7095
Q3 2025 - Record sales and profit growth, with strong FY2026 outlook and expanded shareholder returns.7095
Q4 2025